Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient
The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 m...
Saved in:
| Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 27; no. 2; pp. 387 - 389 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.02.2021
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1341-321X 1437-7780 1437-7780 |
| DOI | 10.1016/j.jiac.2020.12.001 |
Cover
| Abstract | The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. |
|---|---|
| AbstractList | The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4
T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4 + T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients.The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. |
| Author | Kurihara, Yuko Nakajima, Yukiko Anan, Ryusuke Nakano, Yasushi Misaki, Takako Furukawa, Karin Okabe, Nobuhiko Arai, Ryosuke Ogai, Asuca Shimizu, Hideaki |
| Author_xml | – sequence: 1 givenname: Yukiko orcidid: 0000-0003-4039-3593 surname: Nakajima fullname: Nakajima, Yukiko email: 83idakan@city.kawasaki.jp organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 2 givenname: Asuca orcidid: 0000-0002-5665-1676 surname: Ogai fullname: Ogai, Asuca organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 3 givenname: Karin surname: Furukawa fullname: Furukawa, Karin organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 4 givenname: Ryosuke surname: Arai fullname: Arai, Ryosuke organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 5 givenname: Ryusuke surname: Anan fullname: Anan, Ryusuke organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 6 givenname: Yasushi surname: Nakano fullname: Nakano, Yasushi organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 7 givenname: Yuko surname: Kurihara fullname: Kurihara, Yuko organization: Department of Internal Medicine, Kawasaki Municipal Ida Hospital, 211-0035 2-27-1 Ida, Nakahara-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 8 givenname: Hideaki surname: Shimizu fullname: Shimizu, Hideaki organization: Kawasaki City Institute for Public Health, 210-0821 3-25-13 Tono-machi, Kawasaki-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 9 givenname: Takako surname: Misaki fullname: Misaki, Takako organization: Kawasaki City Institute for Public Health, 210-0821 3-25-13 Tono-machi, Kawasaki-ku, Kawasaki City, Kanagawa prefecture, Japan – sequence: 10 givenname: Nobuhiko surname: Okabe fullname: Okabe, Nobuhiko organization: Kawasaki City Institute for Public Health, 210-0821 3-25-13 Tono-machi, Kawasaki-ku, Kawasaki City, Kanagawa prefecture, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33328135$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV1rFDEYhYNU7If-AS9kLr2Zbb5mkhERymKtUFCsinchJu9s33Um2SazC_33ZthWtBf1KiE5z3mTc47JQYgBCHnJ6IJR1p6uF2u0bsEpLwd8QSl7Qo6YFKpWStODsheS1YKzH4fkOOd1EahG62fkUAjBNRPNETn_nOIQwwp8tcNkhypfg_cYVlXsq6uzL1f1Mn6veYWhsqHCcdyG6OK4SXHEXKCNnRDC9Jw87e2Q4cXdekK-nb__uryoLz99-Lg8u6xd07VTLXvhfdN2XmktGtZI6LzopYPeSiZUp61jnXC29Z1VvG0VB9pLTR1I0XIuxAl5t_fdbH-O4F0ZXR5tNglHm25NtGj-vQl4bVZxZ5SeDXgxeH1nkOLNFvJkyj8cDIMNELfZcKloR2kndZG--nvWnyH34RWB3gtcijkn6I3DqeQR59E4GEbN3JNZm7knM_dkGDelhoLyB-i9-6PQ2z0EJeEdQjLZlfAdeEzgJuMjPo6_eYC7AQM6O_yC2__BvwHjp766 |
| CitedBy_id | crossref_primary_10_2169_internalmedicine_9513_22 crossref_primary_10_1080_14737140_2023_2245148 crossref_primary_10_1016_S2665_9913_21_00322_2 crossref_primary_10_7759_cureus_32523 crossref_primary_10_1016_j_clml_2021_07_004 crossref_primary_10_3390_cimb45010003 crossref_primary_10_3390_v14040752 crossref_primary_10_1093_trstmh_trac015 crossref_primary_10_1111_bjh_19143 crossref_primary_10_1002_rcr2_1298 crossref_primary_10_1017_ice_2021_367 crossref_primary_10_7759_cureus_26921 crossref_primary_10_7759_cureus_48319 crossref_primary_10_1186_s12879_021_05886_2 crossref_primary_10_3389_fimmu_2023_1204831 crossref_primary_10_1097_HS9_0000000000000807 crossref_primary_10_5501_wjv_v10_i3_97 crossref_primary_10_1016_j_forsciint_2021_111106 crossref_primary_10_4044_joma_134_171 crossref_primary_10_1007_s40121_024_00987_2 crossref_primary_10_3346_jkms_2023_38_e175 crossref_primary_10_3389_fimmu_2023_1104828 crossref_primary_10_2169_internalmedicine_9136_21 crossref_primary_10_3390_v16030401 crossref_primary_10_1016_j_jiac_2022_01_014 crossref_primary_10_2169_internalmedicine_0241_22 crossref_primary_10_3349_ymj_2024_0129 crossref_primary_10_3348_kjr_2022_0844 crossref_primary_10_1002_cnr2_1669 crossref_primary_10_3348_kjr_2023_1149 crossref_primary_10_1016_j_isci_2024_110729 crossref_primary_10_1099_jmm_0_001498 crossref_primary_10_3947_ic_2024_0046 crossref_primary_10_1016_j_jcv_2023_105499 crossref_primary_10_2147_JIR_S378347 crossref_primary_10_7759_cureus_74380 crossref_primary_10_1097_IPC_0000000000001164 crossref_primary_10_1186_s13256_022_03750_8 crossref_primary_10_3138_jammi_2021_0036 crossref_primary_10_2147_IDR_S477107 crossref_primary_10_2169_internalmedicine_0485_22 crossref_primary_10_1016_j_bjorl_2023_101317 crossref_primary_10_1111_ejh_13967 crossref_primary_10_3390_v13050890 crossref_primary_10_1038_s41467_022_34033_x crossref_primary_10_1093_ofid_ofab195 crossref_primary_10_7759_cureus_57957 crossref_primary_10_3390_jcm11247452 crossref_primary_10_1128_mmbr_00057_21 crossref_primary_10_1007_s40278_021_91536_9 crossref_primary_10_3390_life12101482 crossref_primary_10_1016_j_omtm_2022_02_012 crossref_primary_10_1016_j_clinpr_2022_100210 crossref_primary_10_1016_j_jaip_2021_06_019 crossref_primary_10_3947_ic_2022_0124 crossref_primary_10_1016_j_bjid_2021_101632 crossref_primary_10_1186_s41182_022_00464_x crossref_primary_10_1007_s42770_023_01009_y crossref_primary_10_1016_j_jhin_2021_02_014 crossref_primary_10_1080_10408363_2022_2045250 crossref_primary_10_3389_fmed_2022_1062450 crossref_primary_10_1002_rmv_2471 crossref_primary_10_1093_ofid_ofab217 crossref_primary_10_1186_s12985_022_01891_2 crossref_primary_10_1016_j_immuni_2022_01_014 crossref_primary_10_1093_infdis_jiad272 crossref_primary_10_1136_bcr_2021_243783 crossref_primary_10_1038_s41423_023_01080_3 crossref_primary_10_1097_IPC_0000000000001235 crossref_primary_10_1186_s12879_023_08620_2 crossref_primary_10_22328_2077_9828_2024_16_2_60_68 crossref_primary_10_3390_medicina58060707 |
| Cites_doi | 10.1038/s41586-020-2196-x 10.3324/haematol.2016.152272 10.1016/j.ijid.2020.03.003 10.3109/10428194.2015.1026818 10.7326/M20-0991 10.1056/NEJMc2001737 10.3109/10428194.2015.1110748 |
| ContentType | Journal Article |
| Copyright | 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
| Copyright_xml | – notice: 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases – notice: Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. – notice: 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.jiac.2020.12.001 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1437-7780 |
| EndPage | 389 |
| ExternalDocumentID | PMC7836222 33328135 10_1016_j_jiac_2020_12_001 S1341321X20304360 |
| Genre | Case Reports |
| GroupedDBID | --- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO AAYZH ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGCQF AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF 6I. AACTN AAFTH AAIAV ABLVK ABTEG ABYKQ ADINQ AFKWA AFNRJ AHPSJ AJBFU AJOXV AMFUW EFLBG GQ6 NCXOZ RIG SSI SZN Z7U Z82 Z87 Z8O Z8V Z91 AAYXX AFCTW AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT 5PM |
| ID | FETCH-LOGICAL-c596t-4f3dd569d78835154e9d3f4cefa413798ac193ca6d9a726672e0f480ce4362233 |
| IEDL.DBID | .~1 |
| ISSN | 1341-321X 1437-7780 |
| IngestDate | Thu Aug 21 13:56:26 EDT 2025 Thu Sep 25 09:06:52 EDT 2025 Wed Feb 19 02:29:07 EST 2025 Tue Jul 01 02:23:35 EDT 2025 Thu Apr 24 23:02:39 EDT 2025 Fri Feb 23 02:48:32 EST 2024 Tue Aug 26 16:59:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | SARS-CoV-2 PCR Follicular lymphoma Bendamustine Viral replication Immunocompromised state |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c596t-4f3dd569d78835154e9d3f4cefa413798ac193ca6d9a726672e0f480ce4362233 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0003-4039-3593 0000-0002-5665-1676 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1341321X20304360 |
| PMID | 33328135 |
| PQID | 2470900948 |
| PQPubID | 23479 |
| PageCount | 3 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7836222 proquest_miscellaneous_2470900948 pubmed_primary_33328135 crossref_citationtrail_10_1016_j_jiac_2020_12_001 crossref_primary_10_1016_j_jiac_2020_12_001 elsevier_sciencedirect_doi_10_1016_j_jiac_2020_12_001 elsevier_clinicalkey_doi_10_1016_j_jiac_2020_12_001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-01 |
| PublicationDateYYYYMMDD | 2021-02-01 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| PublicationTitleAlternate | J Infect Chemother |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| References | Chen, Xu, Lei (bib6) 2020; 93 Chen, Qi, Ling (bib10) 2020; 80 Yen, Peiris, Wu (bib4) 2020; 382 Chen, Gao, Xu (bib2) 2020 Mar 30 Colavita, Lapa, Carletti (bib1) 2020 Apr 17 Tsutsumi, Ito, Ohigashi (bib8) 2015; 56 Wolfel, Corman, Guggemos (bib3) 2020; 581 Xia, Tong, Zhang (bib5) 2020 Gafter-Gvili, Polliack (bib7) 2016; 57 Grigg, Dyer, Gonzalez Diaz (bib9) 2017; 102 Chen (10.1016/j.jiac.2020.12.001_bib2) 2020 Colavita (10.1016/j.jiac.2020.12.001_bib1) 2020 Yen (10.1016/j.jiac.2020.12.001_bib4) 2020; 382 Gafter-Gvili (10.1016/j.jiac.2020.12.001_bib7) 2016; 57 Wolfel (10.1016/j.jiac.2020.12.001_bib3) 2020; 581 Chen (10.1016/j.jiac.2020.12.001_bib6) 2020; 93 Tsutsumi (10.1016/j.jiac.2020.12.001_bib8) 2015; 56 Grigg (10.1016/j.jiac.2020.12.001_bib9) 2017; 102 Xia (10.1016/j.jiac.2020.12.001_bib5) 2020 Chen (10.1016/j.jiac.2020.12.001_bib10) 2020; 80 |
| References_xml | – volume: 56 start-page: 3216 year: 2015 end-page: 3218 ident: bib8 article-title: Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma publication-title: Leuk Lymphoma – volume: 80 start-page: e1 year: 2020 end-page: e6 ident: bib10 article-title: Clinical progression of patients with COVID-19 in Shanghai, China publication-title: J Infect – volume: 93 start-page: 297 year: 2020 end-page: 299 ident: bib6 article-title: Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report publication-title: Int J Infect Dis – volume: 382 start-page: 1177 year: 2020 end-page: 1179 ident: bib4 article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients publication-title: N Engl J Med – volume: 581 start-page: 465 year: 2020 end-page: 469 ident: bib3 article-title: Virological assessment of hospitalized patients with COVID-2019 publication-title: Nature – volume: 102 start-page: 765 year: 2017 end-page: 772 ident: bib9 article-title: Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma publication-title: Haematologica – year: 2020 Mar 30 ident: bib2 article-title: SARS CoV-2-positive sputum and feces after conversion of pharyngeal samples in patient with COVID-19 publication-title: Ann Intern Med – start-page: ciaa460 year: 2020 ident: bib5 article-title: Profile of RT-PCR for SARS-CoV-2: preliminary study from 56 COVID-19 patients publication-title: Clin Infect Dis – volume: 57 start-page: 512 year: 2016 end-page: 519 ident: bib7 article-title: Bendamustine associated immune suppression and infection during therapy of hematological malignancies publication-title: Leuk Lymphoma – start-page: M20 year: 2020 Apr 17 end-page: M1176 ident: bib1 article-title: SARS-CoV-2 isolation from Ocular Secretions of a patient with COVID-10 in Italy with prolonged viral RNA detection publication-title: Ann Intern Med – volume: 581 start-page: 465 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib3 article-title: Virological assessment of hospitalized patients with COVID-2019 publication-title: Nature doi: 10.1038/s41586-020-2196-x – start-page: ciaa460 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib5 article-title: Profile of RT-PCR for SARS-CoV-2: preliminary study from 56 COVID-19 patients publication-title: Clin Infect Dis – volume: 102 start-page: 765 issue: 4 year: 2017 ident: 10.1016/j.jiac.2020.12.001_bib9 article-title: Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma publication-title: Haematologica doi: 10.3324/haematol.2016.152272 – volume: 93 start-page: 297 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib6 article-title: Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2020.03.003 – volume: 56 start-page: 3216 issue: 11 year: 2015 ident: 10.1016/j.jiac.2020.12.001_bib8 article-title: Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1026818 – volume: 80 start-page: e1 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib10 article-title: Clinical progression of patients with COVID-19 in Shanghai, China publication-title: J Infect – year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib2 article-title: SARS CoV-2-positive sputum and feces after conversion of pharyngeal samples in patient with COVID-19 publication-title: Ann Intern Med doi: 10.7326/M20-0991 – volume: 382 start-page: 1177 issue: 12 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib4 article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients publication-title: N Engl J Med doi: 10.1056/NEJMc2001737 – start-page: M20 year: 2020 ident: 10.1016/j.jiac.2020.12.001_bib1 article-title: SARS-CoV-2 isolation from Ocular Secretions of a patient with COVID-10 in Italy with prolonged viral RNA detection publication-title: Ann Intern Med – volume: 57 start-page: 512 issue: 3 year: 2016 ident: 10.1016/j.jiac.2020.12.001_bib7 article-title: Bendamustine associated immune suppression and infection during therapy of hematological malignancies publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1110748 |
| SSID | ssj0017588 |
| Score | 2.517198 |
| Snippet | The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 387 |
| SubjectTerms | Antiviral Agents - therapeutic use Bendamustine Case Report COVID-19 - complications COVID-19 - immunology COVID-19 - therapy COVID-19 - virology Follicular lymphoma Humans Immunocompromised Host Immunocompromised state Lymphoma - complications Lymphoma - virology Male Middle Aged Nasopharynx - virology Reverse Transcriptase Polymerase Chain Reaction - methods RNA, Viral - analysis SARS-CoV-2 - isolation & purification SARS-CoV-2 PCR Time Factors Treatment Outcome Viral replication Virus Shedding |
| Title | Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X20304360 https://dx.doi.org/10.1016/j.jiac.2020.12.001 https://www.ncbi.nlm.nih.gov/pubmed/33328135 https://www.proquest.com/docview/2470900948 https://pubmed.ncbi.nlm.nih.gov/PMC7836222 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: ACRLP dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AIKHN dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1437-7780 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5Ceuml9N3tI6hQcmnctSX5oeOydNm2NCzdpOxN2LKUOAQ77G4OufS3d8aWnW5bUujN2BoQo_HMSPrmG4B3hXGusFkcqLJwgcyNIj8YYyKXRralG2nPdL8eJ_NT-XkVr_Zg2tfCEKzS-_7Op7fe2r8Ze22Or6pqvCQqMsGjFafbPZHQvp3Yv9CmP_wYYB4YHdvekzQ4oNG-cKbDeF1UOdEY8rA9EvSNYf4SnP5MPn_HUP4SlGYP4YHPJtmkm_Aj2LP1YzhcdHTUN0fs5La6anPEDtnilqj65gnMFmt8qs9syQjqe8k257akWMYax5aTb8tg2nwPOKtqltesokqShiDo6waNA4U8J-tTOJ19PJnOA99XITCxSraBdKIs40SVuP0VmM9Iq0rhpLEuR42mKssNpnUmT0qVpxjAU25DJ7PQWFQzphPiGezXTW1fAFOWS8GLJHXGSMNtliSGE70UtQtPXTiCqFeoNp50nHpfXOoeXXahaRE0LYKOOEHsRvB-kLnqKDfuHC36ddJ9MSm6P40R4U6peJDaMbd_yr3tTUGjqulyJa9tc73RXKahIpxmNoLnnWkMsxdC8CwS8QjSHaMZBhDH9-6Xujpvub6pyAZTuJf_Od9XcJ8TCKeFmb-G_e362r7BLGpbHLS_yQHcm3z6Mj_-CWvdGvE |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBYlfdhextb9ytatGoy-rCa2JP_QYwgL6dqGsKQjb8KWpdWl2CVJH_rf986W3WYdHezN2DoQp_PdZ-u7T4R8zbS1mUlCT-aZ9USqJebBEIBcHJhabqT-p3s2jSbn4scyXO6QUdsLg7RKl_ubnF5na3dn4Lw5uC6KwRylyDgLlgx393gE3-27IoRbPbI7PD6ZTLvNBIDEdUccjPfQwPXONDSvyyJFJUPm138F3dkwf6lPj_HnnzTKB3Vp_JK8cICSDps5vyI7ptwjh7NGkfr2iC7uG6zWR_SQzu61qm9fk_FsBVflb5NTZPte0fWFybGc0crS-fDn3BtVvzxGi5KmJS2wmaRCFvqqgvgAIyfL-oacj78vRhPPHa3g6VBGG09YnudhJHP4AuYAaYSRObdCG5uCB2OZpBqQnU6jXKYx1PCYGd-KxNcGPA2Igr8lvbIqzXtCpWGCsyyKrdZCM5NEkWaoMIUnhsfW75OgdajSTnccj7-4Ui3B7FLhIihcBBUwZNn1ybfO5rpR3XhyNG_XSbX9pJABFRSFJ63Czmor4v5p96UNBQWuxv2VtDTVzVoxEfsSqZpJn7xrQqObPeecJQEP-yTeCppuAMp8bz8pi4ta7hv7bADFffjP-R6QZ5PF2ak6PZ6efCTPGXJyatb5PultVjfmE4CqTfbZvTR3_AYdnA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prolonged+viral+shedding+of+SARS-CoV-2+in+an+immunocompromised+patient&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Nakajima%2C+Yukiko&rft.au=Ogai%2C+Asuca&rft.au=Furukawa%2C+Karin&rft.au=Arai%2C+Ryosuke&rft.date=2021-02-01&rft.issn=1437-7780&rft.eissn=1437-7780&rft.volume=27&rft.issue=2&rft.spage=387&rft_id=info:doi/10.1016%2Fj.jiac.2020.12.001&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon |